MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition-Reference-Cited by-同舟云学术

MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition

Published:2024-01 Issue:1 Volume:19 Page:160-165
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Riedel Richard,Fassunke Jana,Scheel Andreas H.,Scheffler Matthias,Heydt Carina,Nogova Lucia,Michels Sebastian,Fischer Rieke N.,Eisert Anna,Scharpenseel Heather,John Felix,Ruge Lea,Schaufler Diana,Siemanowski Janna,Ihle Michaela A.,Wagener-Ryczek Svenja,Pappesch Roberto,Rehker Jan,Bunck Anne,Kobe Carsten,Keil Felix,Merkelbach-Bruse Sabine,Büttner Reinhard,Wolf Jürgen

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. MET-dependent solid tumours—molecular diagnosis and targeted therapy;Guo;Nat Rev Clin Oncol,2020

2. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer;Wolf;N Engl J Med,2020

3. The landscape of kinase fusions in cancer;Stransky;Nat Commun,2014

4. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients;Zehir;Nat Med,2017

5. Activating MET kinase rearrangements in melanoma and Spitz tumours;Yeh;Nat Commun,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. c-MET is an important marker for acid-driven metastasis and anti-immune in colorectal cancer;International Immunopharmacology;2024-12

2. Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report;The Oncologist;2024-06-04

3. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations;The Journal of Pathology;2024-02-09

4. Targeting MET in NSCLC: An Ever-Expanding Territory;JTO Clinical and Research Reports;2024-02

5. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC;JTO Clinical and Research Reports;2024-02